Assessing the impact of a typhoid conjugate vaccine introduced in an urban community

Vellore Typhoid Vaccine Impact Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/03/041314

Enrollment

48000

Registered

2022-03-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Typhoid Conjugate Vaccine: Vi Polysaccharide Conjugated to CRM197 (TyphiBEV) delivered as a single intramuscular dose of 0.5 ml. The treatment is given once on a single day at the begin

Eligibility

Inclusion criteria

Inclusion criteria: Provide written informed consent Residents of study area

Exclusion criteria

Exclusion criteria: Has received a typhoid vaccine in the previous three years Is known to have an allergy to any vaccine component Pregnancy or planning pregnancy around vaccination Receipt of any other vaccine in the past 30 days (temporary exclusion) Febrile illness in the 24 hours before vaccination (temporary exclusion)

Design outcomes

Primary

Measure	Time frame
Cumulative number of Blood culture confirmed typhoid feverTimepoint: 24 months after randomization	—

Secondary

Measure	Time frame
Cumulative number of febrile hospitalizationsTimepoint: 24 months after randomization;Number of solicited adverse eventsTimepoint: 7 days after vaccination	—

Countries

India

Contacts

Public ContactJacob John

Christian Medical College Vellore

jebu@cmcvellore.ac.in9442631628

Outcome results